히즈앤어스헬스(HIMS) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

Q: What kind of company is 히즈앤어스헬스(HIMS)?

히즈앤어스헬스(HIMS) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

Q: What is the market cap of HIMS?

The market cap of HIMS is approximately $7.0B, ranking 1,165 within its sector.

Q: What is the 52-week high and low for HIMS?

HIMS has recorded a 52-week high of $70.43 and a low of $13.74.

HIMS

Hims & Hers Health Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$30.24

+2.15 ▲ +7.65%

🌙 7월 27일 7:59 PM ET (한국 7/28 08:59)

$30.06

-0.18 ▼ -0.60%

히즈앤어스헬스(HIMS) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$7.0B

스몰캡

P/E

배당수익률

없음

52주 위치

29%

저점 +120% · 고점 -57%

애널리스트

보유

Fundamental health

vs. Drug Manufacturers - Specialty & Generic

수익성

Top 40%

성장

Top 52%

밸류에이션

Top 9%

재무 안정

Top 30%

Index ⓘ	RUT	P/E ⓘ	-	EPS (ttm) ⓘ	-0.08	Insider Own ⓘ	9.78%	Shs Outstand ⓘ	222.3M	Perf Week ⓘ	-7.52%
Market Cap ⓘ	7.00B	Forward P/E ⓘ	64.3	EPS next Y ⓘ	473.54%	Insider Trans ⓘ	-1.25%	Shs Float ⓘ	208.8M	Perf Month ⓘ	-7.55%
Enterprise Value ⓘ	7.38B	PEG ⓘ	4.22	EPS next Q ⓘ	-0.05	Inst Own ⓘ	66.25%	Short Float ⓘ	29.41%	Perf Quarter ⓘ	-1.05%
Income ⓘ	-0.01B	P/S ⓘ	2.95	EPS this Y ⓘ	-124.69%	Inst Trans ⓘ	-13.77%	Short Ratio ⓘ	3.2	Perf Half Y ⓘ	2.09%
Sales ⓘ	2.37B	P/B ⓘ	15.64	EPS next 5Y ⓘ	15.24%	ROA ⓘ	-0.84%	Short Interest ⓘ	61.41M	Perf YTD ⓘ	-6.87%
Book/sh ⓘ	1.93	P/C ⓘ	9.32	EPS past 3/5Y ⓘ	-	ROE ⓘ	-2.66%	52W High ⓘ	-57.06% ($70.43)	Perf Year ⓘ	-47.55%
Cash/sh ⓘ	3.24	P/FCF ⓘ	113.57	Sales past 3/5Y ⓘ	64.55% 73.63%	ROIC ⓘ	-0.84%	52W Low ⓘ	120.09% ($13.74)	Perf 3Y ⓘ	259.57%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	63.91	EPS Y/Y TTM ⓘ	-107.11%	Gross Margin ⓘ	57.45%	Volatility(W/M) ⓘ	11.63% 8.62%	Perf 5Y ⓘ	268.78%
Dividend TTM ⓘ	-	EV/Sales ⓘ	3.11	Sales Y/Y TTM ⓘ	32.81%	Oper. Margin ⓘ	2%	ATR (14) ⓘ	2.8	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	1.55	EPS Q/Q ⓘ	-301%	Profit Margin ⓘ	-0.56%	RSI (14) ⓘ	43.84	Recom ⓘ	2.72
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	1.69	Sales Q/Q ⓘ	3.77%	SMA20 ⓘ	-11.6% ($34.21)	Beta ⓘ	2.41	Target Price ⓘ	$30.69
Payout ⓘ	-	Debt/Eq ⓘ	2.54	Earnings ⓘ	2026/8/10	SMA50 ⓘ	-0.59% ($30.42)	Rel Volume ⓘ	0.84	Prev Close ⓘ	$28.09
Employees ⓘ	2442	LT Debt/Eq ⓘ	2.52	EPS/Sales Surpr. ⓘ	-1674.8% -1.42%	SMA200 ⓘ	-2.19% ($30.92)	Avg Volume(3M) ⓘ	19.16M	Price ⓘ	$30.24
IPO ⓘ	2019/9/13	Option/Short ⓘ	Yes/Yes			Trades ⓘ	68771	Volume ⓘ	16,106,254	Change ⓘ	7.65%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $608M (YoY +4%) · 순이익 $-92M (YoY -286%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Hims & Hers Health Inc (HIMS) Investment Analysis

What kind of company is Hims & Hers Health Inc?

히즈앤어스헬스(HIMS) 초고성장주

Healthcare · Drug Manufacturers - Specialty & Generic

#1165 by Market Cap — Mid-Cap

A U.S. healthcare company that operates a consumer-direct (D2C) telehealth platform. It connects patients with online consultations and prescriptions, offering personalized treatments and subscription-based products in areas such as hair loss, sexual health, weight loss, mental health, and skincare. Its performance is tied to subscriber numbers, average revenue per user, and the regulatory environment, making it a healthcare stock sensitive to those factors.

Learn more about Hims & Hers Health Inc →

Market Cap

$7.0B

Approx. KRW 9.6 trillion

⚖️ 2% of Samsung Electronics

Market Cap Rank1165

Employees2,442people

IPO2019/09/13

Current Price$30.24 ≈ 41,429원

📌 RUT · NYSE · USA

Key Events

⏰ Upcoming events

🔔 Earnings release D-13

8월 10일 (월) · 장 마감 후

예상 매출 - · EPS $0.11

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 11일 (월) · 장 마감 후 EPS -1674.8% 매출 -1.4%

🔔 Earnings release 2026년 2월 23일 (월) · 장 마감 후 EPS +100.5% 매출 -0.2%

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

2.0%

✓ 양호

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median -7.1% · Top 39%

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

-0.6%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

57.5%

✓ 양호

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 52.5% · Top 41%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-2.7%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-0.8%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-0.8%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

2.54

✓ Very high debt

My positionBottom 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 0.36

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

1.69

✓ 양호

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 2.47

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

1.55

✓ 양호

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 1.68

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$30.69

현재가 대비 +1.5%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

64.30배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

PEG (성장 반영 밸류)

4.22

고평가

💡 PEG > 2 — 성장 대비 비싼 편

내년 EPS 예상 성장률

+473.5%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

+15.2%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance

Mixed beats and misses

예상 상회

예상 부합

예상 하회

50%

상회 비율

-587.7%

평균 서프라이즈

2026.05.11

하회

실적 $-0.40 · 예상 $0.03 -1267.9%

2026.02.23

상회

실적 $0.08 · 예상 $0.04 +92.5%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth

Mid-range within the industry

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

-124.7%

매우 부진

My positionBottom 5%

Low range Average High range

초고성장주 중형주 Median 49.3% · Bottom tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+473.5%

우수

My positionTop 5%

Low range Average High range

초고성장주 중형주 Median 31.3% · Top tier

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

+15.2%

부진

My positionBottom 25%

Low range Average High range

초고성장주 중형주 Median 39.1% · Bottom 17%

📊 How much has it grown? (actual results)

Past 5-Year Revenue

How much revenue grew over the past 5 years

+73.6%

우수

My positionTop 5%

Low range Average High range

초고성장주 중형주 Median 30.4% · Top tier

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+3.8%

평균

My positionMid-range

Low range Average High range

초고성장주 중형주 Median 18.9% · Bottom 25%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Outperformed the market by 200%p over 5 years

HIMS +268.8% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

+200.4%p

well ahead of the market

vs Health Care (XLV)

+244.3%p

well ahead of the sector average

1-year basis

vs S&P 500

-63.6%p

Significantly behind the market

vs Health Care (XLV)

-67.3%p

Significantly behind the sector average

Rank among peers

5-year return Upper-Mid (42%) Based on 12 peers

1-year return Bottom 12% Based on 12 peers

Current position within 52-week range

Low (-120.1%p) High (-57.1%p)

Current price is 120.1% above the 52-week low and 57.1% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-40.5%

Annualized volatility

104.1%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-27

Downtrend zone

Current price $30.24 below the midline ($34.21). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴

Current diagnosis · 2026-07-27

Bearish momentum holding

MACD -0.198 < Signal 0.709 in negative zone + Hist negative (-0.906). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-07-27

Bearish zone

RSI 43.8 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 23.7.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry

Pricey on Vs. Earnings·Vs. Assets·Vs. Cash Flow, In line with peers on Vs. Sales

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Pricey

🏢 Vs. Assets Pricey

🧾 Vs. Sales Mid-range

💧 Vs. Cash Flow Pricey

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

64.30x

✓ Very pricey

My positionBottom 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic median 14.70x · Bottom 1% — expensive within the industry

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

15.64x

✓ Very pricey

My positionBottom 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic median 1.55x · Bottom 1% — expensive within the industry

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

2.95x

✓ Fair

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic median 2.13x · Around the industry average

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

63.91x

✓ Very pricey

My positionBottom 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic median 10.57x · Bottom 1% — expensive within the industry

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

113.57x

✓ Very pricey

My positionBottom 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic median 18.10x · Bottom 1% — expensive within the industry

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$30.69 vs. current price +1.5%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic

Who owns it?

Ownership backdrop is unfavorable

Insider modest net selling -1.3% · Institutional net selling -13.8% · Short interest very high 29.4% · Short interest fell -11.6%p over the last 90 days

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-1.3%

Insiders net selling

🏦 Institutions (funds & investors)

-13.8%

Institutions large net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 66.3%

Adequate institutional weight

Healthcare 중형주 Median 89.4%

🧑‍💼 Insiders 9.8%

Meaningful insider stake

Healthcare 중형주 Median 9.4%

👤 Retail investors (estimated) 24.0%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

29.4%

Very high — strong short-side pressure

Healthcare 중형주 Median 11.3%

Past 90 days 📉 -11.6%p decrease

Short interest days to cover

3.2 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 222.3M주

Float (tradable shares) 208.8M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding HIMS

ETFs with the highest weightings · 10 total shown

BUZZ

VanEck Social Sentiment ETF

2.79%

$92M

EKG

First Trust Nasdaq Lux Digital Health Solutions ETF

2.24%

$4M

XHS

State Street SPDR S&P Health Care Services ETF

1.62%

$206M

HEAL

Global X HealthTech ETF

1.61%

$28M

DBSC

Deepwater Beachfront Small Cap ETF

1.42%

$5M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
HIMS This Stock	$7.0B	-	15.6 ▼	-2.66% ▲	-	+7.7%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

Derivative ETFs for HIMS

Leveraged, inverse, and covered call ETFs based on the underlying asset

3 derivative ETFs based on HIMS (Leverage 2 · Covered Call 1)

These are based on the same underlying asset but carry a completely different risk and return profile. Please review the warning below first.

ℹ️ What is a Derivative ETF?

These are special ETFs that amplify, reverse, or monetize the price movement of an underlying ETF or security. Leveraged ETFs aim for 2–3× the daily move, Inverse ETFs target opposite-direction returns, and Covered Call ETFs generate monthly income from option premiums.

⚠️ Caution: Long-Term Holding

Leveraged and inverse ETFs track only the daily return. With high volatility, holding them for longer periods causes cumulative volatility decay—returns diverge further from the underlying index. They are meant for short-term trading.

📈 Leverage 2 ETFs that move 2-3x with HIMS (high volatility)